(Q38090552)

28 August 2017

PCA3 in the detection and management of early prostate cancer (English)

1 reference

28 August 2017

1 reference

Josep Maria Auge Fradera

0 references

author name string

Xavier Filella

1

1 reference

28 August 2017

Laura Foj

2

1 reference

28 August 2017

Montserrat Milà

3

1 reference

28 August 2017

Josep M Augé

4

1 reference

28 August 2017

Rafael Molina

5

1 reference

28 August 2017

Wladimiro Jiménez

6

1 reference

28 August 2017

16 March 2013

1 reference

28 August 2017

1 reference

28 August 2017

34

1 reference

28 August 2017

1337-1347

1 reference

28 August 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1007/s13277-013-0739-6

28 August 2017

0 references

cites work

Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

Defining and predicting indolent and low risk prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

From prostate-specific antigen (PSA) to precursor PSA (proPSA) isoforms: a review of the emerging role of proPSAs in the detection and management of early prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

Evaluation of [-2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

uPM3, a new molecular urine test for the detection of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

DD3PCA3 RNA analysis in urine--a new perspective for detecting prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

A duplex quantitative polymerase chain reaction assay based on quantification of alpha-methylacyl-CoA racemase transcripts and prostate cancer antigen 3 in urine sediments improved diagnostic accuracy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

The combination of urine DD3(PCA3) mRNA and PSA mRNA as molecular markers of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

A three-gene panel on urine increases PSA specificity in the detection of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

The diagnostic value of PCA3 gene-based analysis of urine sediments after digital rectal examination for prostate cancer in a Chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

Assessment of the PCA3 test for prostate cancer diagnosis: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

PCA3: a molecular urine assay for predicting prostate biopsy outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

Urinary prostate cancer 3 test: toward the age of reason?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

Contemporary role of prostate cancer gene 3 in the management of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in Prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (≥ 100).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

Predicting prostate cancer risk through incorporation of prostate cancer gene 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

Prostate cancer detection in the "grey area" of prostate-specific antigen below 10 ng/ml: head-to-head comparison of the updated PCPT calculator and Chun's nomogram, two risk estimators incorporating prostate cancer antigen 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

The relationship between Prostate CAncer gene 3 (PCA3) and prostate cancer significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

The value of urinary prostate cancer gene 3 (PCA3) scores in predicting pathological features at radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

Relationship between prostate cancer gene 3 (PCA3) and characteristics of tumor aggressiveness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

PCA3 molecular urine assay for prostate cancer: association with pathologic features and impact of collection protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

Natural History of Early, Localized Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-0739-6

The role of urine prostate cancer antigen 3 mRNA levels in the diagnosis of prostate cancer among Hong Kong Chinese patients.

21 January 2018

1 reference

12 December 2020

DD3: a new prostate-specific gene, highly overexpressed in prostate cancer

1 reference

12 December 2020

Overdiagnosis Due to Prostate-Specific Antigen Screening: Lessons From U.S. Prostate Cancer Incidence Trends

1 reference

12 December 2020

Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay

1 reference

12 December 2020

Predicting prostate biopsy outcome using a PCA3-based nomogram in a Polish cohort

1 reference

12 December 2020

Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance

1 reference

12 December 2020

PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine.

1 reference

12 December 2020

[Outcomes of expanded use of PCA3 testing in a Spanish population with clinical suspicion of prostate cancer]

1 reference

12 December 2020

DD3(PCA3), a very sensitive and specific marker to detect prostate tumors

1 reference

12 December 2020

Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer

1 reference

12 December 2020

10.1007/S13277-013-0739-6

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

0 references

1 reference